Patents by Inventor Céline Jaillard
Céline Jaillard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220404376Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.Type: ApplicationFiled: July 18, 2022Publication date: December 22, 2022Inventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch
-
Patent number: 11428698Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.Type: GrantFiled: December 12, 2019Date of Patent: August 30, 2022Assignees: Institut National de la Santé et de la Recherche Médicale, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQU—CNRSInventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch
-
Publication number: 20200174023Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.Type: ApplicationFiled: December 12, 2019Publication date: June 4, 2020Inventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch
-
Publication number: 20190064189Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.Type: ApplicationFiled: October 2, 2018Publication date: February 28, 2019Inventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch
-
Patent number: 9575075Abstract: The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO:10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.Type: GrantFiled: June 5, 2008Date of Patent: February 21, 2017Assignees: INSERM (Institut National de la Sante et Recherche Medicale), Centre National de la Recherche Scientifique (CNRS)Inventors: Thierry Leveillard, José-Alain Sahel, Céline Jaillard, Olivier Poch
-
Publication number: 20170014478Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.Type: ApplicationFiled: July 8, 2016Publication date: January 19, 2017Inventors: Thierry Leveillard, José-Alain Sahel, Céline Jaillard, Olivier Poch
-
Patent number: 8779093Abstract: This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.Type: GrantFiled: September 10, 2009Date of Patent: July 15, 2014Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Thierry Leveillard, Celine Jaillard, Jose-Alain Sahel
-
Publication number: 20120245093Abstract: This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.Type: ApplicationFiled: September 10, 2009Publication date: September 27, 2012Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Thierry Leveillard, Celine Jaillard, Jose-Alain Sahel
-
Publication number: 20100247496Abstract: The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO:10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.Type: ApplicationFiled: June 5, 2008Publication date: September 30, 2010Applicant: Institute National De La Sante ET De Las Recherche Medicale (INSERM)Inventors: Thierry Leveillard, José-Alain Sahel, Céline Jaillard, Olivier Poch